Table 2. Metabolites that significantly differentiated placental abruption cases and controls via quantitative targeted analyses.
| Metabolite | Limit of Detection | Abruption cases | Controls | Fold * | ||
|---|---|---|---|---|---|---|
| Classification | Analyte | (LOD) | (N = 51) | (N = 51) | change | P-value** |
| Mean ± SD | Mean ± SD | |||||
| Acylcarnitines | C16-OH | 0.016 | 0.015 ± 0.0038 | 0.017 ± 0.0042 | -1.12 | 0.021 |
| Amino Acids | Arg† | 1.64 | 197.63 ± 71.55 | 233.84 ± 90.99 | -1.18 | 0.029 |
| Biogenic Amines | Histamine | 1.04 | 0.37 ± 0.01 | 0.37 ± 0.01 | +1.01 | 0.034 |
| Custom Ratios*** | C12 / C12:1 | C12 LOD: 0.09 | 1.16 ± 0.19 | 1.09 ± 0.19 | +1.07 | 0.045 |
| C12:1 LOD: 0.066 | ||||||
| Glycerophospholipids | PC ae C38:1 | 0.033 | 5.71 ± 1.61 | 6.63 ± 2.29 | -1.16 | 0.021 |
| Glycerophospholipids | PC aa C40:1 | 0.472 | 0.56 ± 0.16 | 0.64 ± 0.22 | -1.14 | 0.038 |
| Glycerophospholipids | PC aa C36:0 | 0.273 | 1.91 ± 0.78 | 2.33 ± 1.18 | -1.22 | 0.040 |
| Glycerophospholipids | lysoPC a C18:1 | 0.183 | 15.54 ± 7.76 | 18.96 ± 8.76 | -1.22 | 0.040 |
| Glycerophospholipids | PC aa C38:0 | 0.047 | 2.03 ± 0.71 | 2.34 ± 0.84 | -1.15 | 0.048 |
| Custom Ratios*** | High C12/C12:1 | C12 LOD: 0.09 | 25 (49.02%)†† | 14 (27.45%)†† | — | 0.025 |
| Low C12/C12:1 | C12:1 LOD: 0.066 | 26 (50.98%)†† | 37 (72.55%)†† | — |
High C12/C12:1 = C12 / C12:1 > 1.2; Low C12/C12 = C12:1 ≤ 1.2
*Fold change (placental abruption case/control)
**p-values based on Student t tests with Satterthwaite approximation for continuous variables and chi-square test for categorical variables
***Ratio of dodecanoylcarnitine/dodecenoylcarnitine (C12 / C12:1)
†n = 50
††Cell count (%)